Prestige Consumer Healthcare Inc

Despite recent challenges, including disappointing earnings primarily due to ongoing supply constraints in its eye care segment, we believe Prestige Consumer Healthcare is well positioned to navigate near-term challenges and drive long-term growth. Management's focus on product quality, disciplined execution, and targeted expansion supports our positive outlook. The company's strategic initiatives and portfolio strength are expected to enhance its competitive position in the consumer health market.

Despite being a defensive consumer-health business, Prestige Consumer Healthcare, Inc. (PBH) plummeted -20.2% during the quarter. This decline occurred in an environment where companies built to perform during rising prices and conflict were badly battered, indicating potential challenges ahead for the business. The performance suggests that even traditionally stable sectors can face significant volatility, raising concerns about the company's resilience in the current market conditions.

Prestige Consumer Healthcare (PBH) faced challenges this quarter due to supply chain issues affecting its eye care business, leading to missed earnings forecasts. However, the company is taking proactive steps to resolve these issues by acquiring its eye care supplier for $100 million, which will allow for focused production. We anticipate a rebound in PBH's earnings for FY 2027 as the core business is performing well and inventory restocking occurs. At a price of $63, shares are trading at 13.8 times 2027 earnings, and we expect multiple expansion as earnings accelerate post-resolution of supply chain challenges.

Prestige Consumer Healthcare (PBH) faced challenges this quarter due to supply chain issues affecting its eye care business, leading to missed earnings forecasts. However, the company is taking proactive steps by acquiring its eye care supplier for $100 million, which will enhance production capabilities. We anticipate a strong rebound in PBH's earnings for FY 2027 as the core business remains robust and inventory restocking occurs. At a price of $63, shares are trading at 13.8 times 2027 earnings, and we expect multiple expansion as earnings accelerate post-supply chain resolution.